MYGN

+ Watchlist + Portfolio

Myriad Genetics, Inc.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.54
52-Week Range: $2.74 – $8.59
Market Cap: $438.08M
P/E (TTM): —
EPS (TTM): -1.18
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.44
PEG Ratio: 1.24
Return on Equity: -32.54%
Return on Assets: -8.60%
Gross Margin: 68.83%
Operating Margin: -20.40%
Profit Margin: -13.96%
Current Ratio: 2.21
Debt/Equity: 0.69
Total Debt: $210.50M
Free Cash Flow: $18.19M
Revenue Growth: -10.50%
Earnings Growth: —
Enterprise Value: $529.55M

MYGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$678.40M	$753.20M	$837.60M	$824.50M
Cost of Revenue	$202.00M	$236.20M	$252.20M	$247.90M
Gross Profit	$476.40M	$517.00M	$585.40M	$576.60M
Research & Development	$85.40M	$88.70M	$113.40M	$106.80M
Selling, General & Admin	$514.70M	$572.90M	$560.00M	$537.60M
Operating Expenses	$600.10M	$661.60M	$673.40M	$644.40M
Operating Income	-$123.70M	-$144.60M	-$88.00M	-$67.80M
EBITDA	-$84.70M	-$197.40M	-$59.50M	-$330.90M
Pretax Income	-$140.60M	-$262.20M	-$123.50M	-$395.10M
Income Tax	-$28.60M	$1.10M	$3.80M	-$29.20M
Net Income	-$112.00M	-$263.30M	-$127.30M	-$365.90M
Diluted EPS	-1.39	-3.18	-1.41	-3.95
Diluted Shares	80.60M	82.80M	90.60M	92.60M

MYGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$56.90M	$132.10M	$102.40M	$149.60M
Receivables	$101.60M	$114.30M	$121.20M	$115.30M
Inventory	$20.10M	$22.00M	$27.50M	$30.60M
Current Assets	$274.60M	$313.60M	$298.00M	$332.60M
Total Assets	$1.20B	$1.15B	$1.03B	$706.60M
Current Liabilities	$137.20M	$155.90M	$164.10M	$133.80M
Long-Term Debt	—	$38.50M	$39.60M	$119.90M
Total Debt	$145.00M	$152.10M	$140.30M	$209.80M
Total Liabilities	$312.90M	$363.30M	$326.50M	$338.60M
Retained Earnings	-$366.20M	-$629.50M	-$756.80M	-$1.12B
Shareholders' Equity	$885.80M	$783.20M	$701.10M	$368.00M
Working Capital	$137.40M	$157.70M	$133.90M	$198.80M

MYGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$106.30M	-$110.90M	-$8.70M	$1.80M
Capital Expenditure	-$45.30M	-$73.30M	-$29.70M	-$27.40M
Free Cash Flow	-$151.60M	-$184.20M	-$38.40M	-$25.60M
Depreciation & Amortisation	$52.70M	$61.90M	$61.20M	$53.70M
Stock-Based Compensation	$38.10M	$40.70M	$49.80M	$35.20M
Investing Cash Flow	-$77.50M	$31.90M	-$11.90M	-$27.40M
Financing Cash Flow	-$8.00M	$152.90M	-$7.40M	$64.20M
Net Change in Cash	-$191.80M	$73.90M	-$28.00M	$38.60M

MYGN Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$213.10M	$205.70M	$209.80M	$200.40M	—
Cost of Revenue	$61.30M	$61.90M	$63.00M	$62.80M	—
Gross Profit	$151.80M	$143.80M	$146.80M	$137.60M	—
Research & Development	$25.60M	$28.20M	$25.50M	$27.10M	—
Selling, General & Admin	$138.70M	$138.90M	$124.30M	$135.80M	—
Operating Expenses	$164.30M	$167.10M	$149.80M	$162.90M	—
Operating Income	-$12.50M	-$23.30M	-$3.00M	-$25.30M	—
EBITDA	-$315.00M	-$9.80M	$8.10M	-$17.50M	—
Pretax Income	-$330.60M	-$26.20M	-$8.90M	-$34.10M	—
Income Tax	-$100.00K	$1.20M	-$1.00M	$0.00	—
Net Income	-$330.50M	-$27.40M	-$7.90M	-$34.10M	—
Diluted EPS	-3.57	-0.29	-0.08	-0.36	-0.46
Diluted Shares	92.50M	93.10M	93.30M	93.70M	94.80M

MYGN Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$74.40M	$145.40M	$149.60M	$124.40M	—
Receivables	$137.00M	$118.00M	$115.30M	$123.80M	—
Inventory	$28.70M	$31.60M	$30.60M	$27.90M	—
Current Assets	$284.30M	$344.80M	$332.60M	$312.80M	—
Total Assets	$677.30M	$728.10M	$706.60M	$673.70M	—
Current Liabilities	$199.90M	$148.00M	$133.80M	$130.20M	—
Long-Term Debt	—	$119.50M	$119.90M	$120.30M	—
Total Debt	$154.60M	$212.30M	$209.80M	$211.50M	—
Total Liabilities	$289.20M	$355.30M	$338.60M	$336.30M	—
Retained Earnings	-$1.09B	-$1.11B	-$1.12B	-$1.16B	—
Shareholders' Equity	$388.10M	$372.80M	$368.00M	$337.40M	—
Working Capital	$84.40M	$196.80M	$198.80M	$182.60M	—

MYGN Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$16.30M	-$13.60M	$21.10M	$10.60M	-$15.70M
Capital Expenditure	-$8.30M	-$6.90M	-$6.20M	-$6.00M	-$6.50M
Free Cash Flow	-$24.60M	-$20.50M	$14.90M	$4.60M	-$22.20M
Depreciation & Amortisation	$14.40M	$14.10M	$12.60M	$12.60M	$12.50M
Stock-Based Compensation	$9.50M	$10.70M	$12.20M	$2.80M	$6.50M
Investing Cash Flow	-$8.30M	-$6.90M	-$6.20M	-$6.00M	-$6.50M
Financing Cash Flow	$13.60M	$2.60M	$56.20M	-$8.20M	-$3.00M
Net Change in Cash	-$11.00M	-$17.90M	$71.10M	-$3.60M	-$25.20M

Market Snapshot

About

Myriad Genetics is a molecular diagnostics company that develops and markets genetic tests for assessing hereditary cancer risk, tumor profiling, and prenatal screening. The company provides precision medicine solutions helping clinicians make personalized treatment decisions based on genetic information.